Hester Biosciences Limited

Hester Biosciences Limited

Hester Biosciences Limited has informed the Exchange about Credit Rating upgrade by CARE Ratings Limited.

Hester Biosciences Limited

Hester Biosciences Limited has informed the Exchange regarding Notice of Postal Ballot for obtaining the approval of members for Reclassification of persons forming part of the Promoter Group from 'Promoter' Shareholder to 'Public' Shareholder.

Hester Biosciences Limited

Hester Biosciences Limited has informed the Exchange about the transcript of the earnings conference call held on 30 July 2026 to discuss the financial results for the quarter ended 30 June 2026. The company's revenue from operations grew by 14% and PAT increased by 88% over the corresponding quarter of the previous year. The Poultry Healthcare Division delivered an excellent quarter, recording 48% growth over the corresponding quarter of the previous year.

Hester Biosciences Limited

Hester Biosciences Limited has launched an interactive microsite for its 39th Annual Report FY 2025–26, providing a digital and accessible format for stakeholders to view key financial, operational, and strategic highlights.

Hester Biosciences Limited

Hester Biosciences Limited has submitted a copy of the published extract of consolidated unaudited financial results for the quarter ended 30 June 2026, along with information on standalone financial results, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Hester Biosciences Limited

Hester Biosciences Limited has informed the Exchange about the link of recording of the earnings conference call on the financial results for the quarter ended 30 June 2026.

Hester Biosciences Limited

Hester Biosciences Limited has announced its unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, showing a 14% increase in standalone revenue and an 88% increase in standalone profit, while consolidated revenue decreased by 8% and consolidated profit increased by 459% due to an exceptional gain from the amendment of the Gates Foundation loan at Hester Africa.

Hester Biosciences Limited

Hester Biosciences Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a profit before exceptional items and tax of ₹197.52 crore and a profit after exceptional item and tax of ₹147.11 crore. The company has also announced the divestment of 43.81% equity shareholding in its subsidiary, Texas Lifescience Private Limited.

Hester Biosciences Limited

Hester Biosciences Limited has scheduled an investor interaction through a teleconference call on July 30, 2026, to discuss Q1FY27 financial results.

Hester Biosciences Limited

Hester Biosciences Limited has received no-objection letters from NSE and BSE for the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from the promoter group to the public category.

Hester Biosciences Limited

Hester Biosciences Limited has held its 39th Annual General Meeting on July 21, 2026, via video conferencing, where all resolutions were passed with the requisite majority. The meeting was attended by 59 members, representing 56.38% of the total paid-up equity share capital.

Hester Biosciences Limited

Hester Biosciences Limited has transferred its remaining 11% equity shares in Texas Lifesciences Private Limited to existing shareholders for an aggregate consideration of INR 23 million, reducing its shareholding to nil.

Hester Biosciences Limited

Hester Biosciences Limited has informed the Exchange about the transfer of equity shares to the Investor Education and Protection Fund (IEPF) as per SEBI regulations.

Hester Biosciences Limited

Hester Biosciences Limited has published a copy of a newspaper advertisement for a corrigendum to the notice convening its 39th Annual General Meeting.

Hester Biosciences Limited

Hester Biosciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, regarding securities dematerialisation and rematerialisation during the quarter ended 30 June 2026.

Hester Biosciences Limited

Hester Biosciences Limited has issued a corrigendum to its notice of Annual General Meeting (AGM) to be held on July 21, 2026, correcting a typographical error in the remuneration terms of an Executive Director.

Hester Biosciences Limited

Hester Biosciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed from 1 July 2026 and will end 48 hours after the financial results of the Company for the quarter ended 30 June 2026 become generally available as public information.

Hester Biosciences Limited

Hester Biosciences Limited has informed the Exchange about the publication of newspaper advertisements on June 19, 2026. These advertisements serve as the official Notice for the company's 39th Annual General Meeting (AGM). The notice includes crucial details regarding the dividend proposal and e-voting information for shareholders. This disclosure ensures regulatory compliance and provides investors with essential information to participate in the upcoming AGM and be aware of dividend-related decisions.

Hester Biosciences Limited

Hester Biosciences Limited has fixed the record date for the purpose of dividend and meeting as 14-Jul-2026.

Hester Biosciences Limited

Hester Biosciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 21, 2026, along with the Annual Report for the financial year 2025-26.